Dr. Francisco Arredondo Opens First U.S. INVOcell Center in McAllen, Texas
MCALLEN, Texas and MEDFORD, Mass., September 06, 2017 — INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced the opening of the United States’ first fertility center to exclusively offer the INVOcell device and solution to patients. The INVOcell center is an extension of RMA of Texas, a leading provider of fertility-based solutions with multiple locations in Texas. The INVOcell center, based in McAllen, Texas, is under the direction of Dr. Francisco Arredondo, MD, a respected and experienced board certified reproductive endocrinologist, who has published numerous papers on infertility.
Branded by Dr. Arredondo as Smart IVF, the center will offer INVOcell’s patented medical device that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. By utilizing the women’s own body as an incubator, it decreases the number of office visits, blood work, monitoring and other costs associated with traditional in vitro fertilization (IVF). These decreased input costs translate into an approximate 50% reduction in the overall cost per cycle for patients. Despite the decreased costs, pregnancy rates with INVOcell are equivalent to that of traditional IVF.
Francisco Arredondo, MD MPH, founder of Smart IVF, a subsidiary of RMA of Texas, commented “INVOcell is a true breakthrough for infertility treatment. I began offering the INVOcell solution to patients at my fertility clinics in San Antonio and Austin in April 2016. Due to the success we had in expanding the accessibility of infertility treatment to patients, we decided to open a center where we would exclusively offer the INVOcell solution. Since our pre-launch in April 2017, we have now treated 68 patients in our new McAllen location. I am excited about the opportunity afforded to us by INVOcell to bring an effective and affordable fertility treatment option to Southern Texas.”
“Dr. Arredondo has been an early champion of the INVOcell solution,” said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “The successful launch of a clinic exclusively offering INVOcell in McAllen, Texas, a location void of traditional IVF centers, validates a number of assumptions we have about the opportunity to expand accessibility to fertility treatment. We look forward to working with Dr. Arredondo and other physicians around the United States to bring INVOcell centers to large metropolitan areas, as well as smaller remote locations, where traditional IVF centers would be financially unfeasible.”
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
SMART IVF. McAllen Texas
Simple. Mindful. Affordable. Reproductive Technology
Dr. Francisco Arredondo